


Amendments to the Claims

This listing will replace all prior versions, and listings, of the claims in the application:



Listing of Claims:

Claim 1 (Currently amended): ~~The triptolide~~ Triptolide derivatives having the structure represented by the formula (1) shown as below, or pharmaceutically acceptable salts thereof, or their optical diastereoisomers:




~~Wherein~~ wherein C-5 and C-6 are connected through single or double carbon-carbon bond; when C-5 and C-6 are connected by single bond, X and Y independently represent hydrogen, oxygen, hydroxyl, halogen, alkoxy, mercapto, $-NR_1R_2$, $-SR$, $-OCOR$, $-OSO_2OR$, or $-OPO(OH)_2$ linked to C-5 or C-6, in which R is $-(CH_2)_nCO_2Na$, $-(CH_2)_nCO_2K$ ~~或~~ or $-(CH_2)_nCH_3$, and $n=1-6$;

Z is hydrogen, oxygen, hydroxyl, halogen, alkoxy, mercapto, $-NR_1R_2$, $-SR$, $-OCOR$, $-OSO_2OR$, or $-OPO(OH)_2$ linked to C-14, in which R is $-(CH_2)_nCO_2Na$, $-(CH_2)_nCO_2K$ *** $-(CH_2)_nCH_3$, $n=1-6$;


~~In~~ in the above formula (1), “-“ that attaches to “X”, “Y” and “Z” represents the stereochemistry orientations “” and “” as well; and

X and Y are not allowed to be hydrogen at the same time.


Claim 2 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to ~~of~~ claim 1, wherein the configuration of X is a (R), that of Y is (R) or (S), and Z is β -OH(R) shown as formula (2):




Claim 3 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to ~~of~~ claim 1, wherein the configuration of X is α (R), that of Y (R) or (S), and Z is α -OH(s) shown as formula (3):



Claim 4 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to ~~of~~ claim 1, wherein the configuration of X is a (R), that of Y (R) or (S), and Z is O shown as formula (4):



Claim 5 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to ~~of~~ claim 1, wherein C-5 and C-6 are connected by double bond, and the configuration of Z is R or S, or Z=O as shown formula (5):



Claim 6 (Currently amended): ~~The triptolide~~ Triptolide derivatives according to ~~of~~ claim 1, which comprise including the following: (5R)-5-hydroxytriptonide, (5R)-5-hydroxytriptolide, (5R)-5-hydroxy-14-epitriptolide, $\Delta^{5,6}$ -dehydrotriptonide, $\Delta^{5,6}$ -dehydrotriptolide, $\Delta^{5,6}$ -dehydro-14-epitriptolide, (5R,6S)-5,6-epoxytriptonide, (5R,6S)-5,6-epoxytriptolide, (5R,6S)-5,6-epoxy-14-epitriptolide, *cis*-(5R,6S)-5,6-dihydroxytriptonide, *cis*-(5R,6S)-5,6-dihydroxytriptolide, *cis*-(5R,6S)-5,6-dihydroxy-14-epitriptolide.

Claim 7 (Currently amended): ~~A The application of the triptolide derivatives of claim 1 in preparing antinflamable agent, immunosuppressant agent or other pharmaceutical composition prepared from the triptolide derivatives of claim 1. compositions in treating related diseases.~~

Claim 8 (Currently amended): A method of treating at least one of ~~The application of claim 7,~~ wherein ~~the related diseases include~~ autoimmune diseases, including arthritis, diseases (arthritis, systemic lupus erythematosus, chronic nephritis, ~~diabetes); diabetes and inflammatory diseases,~~ including AIDS, diseases (AIDS, virus hepatitis); allergy; hepatitis, and allergies and skin diseases, and cardiovascular diseases, diseases and transplant rejection, as well as rejections, and

anti-fertility and immune related diseases- diseases which comprises administering the pharmaceutical composition of Claim 7.

Claim 9 (New): A pharmaceutical composition according to claim 7 which comprises at least one of and antinflamable agent, and an immunosuppressant.

Claim 10 (New): A method of treating at least one of an autoimmune disease and an inflammatory disease which comprises administering the pharmaceutical composition of Claim 9.